CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome

ESSENTIAL (EULAR Sjögren's Syndrome Study Group); HarmonicSS (H2020); Serena Colafrancesco; Roberta Priori; Charlotte Smith; Antonina Minniti; Valentina Iannizzotto; Elena Pipi; Davide Lucchesi; Elena Pontarini; Saba Nayar; Joana Campos; Francesca Arienzo; Massimo Fusconi; Bruna Cerbelli; Carla Giordano; Guido Valesini; Michele Bombardieri; Benjamin Fisher; Francesca Barone

doi:10.1093/rheumatology/kez255

CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome

ESSENTIAL (EULAR Sjögren's Syndrome Study Group)
, HarmonicSS (H2020)
, Serena Colafrancesco
, Roberta Priori
, Charlotte Smith
, Antonina Minniti
, Valentina Iannizzotto
, Elena Pipi
, Davide Lucchesi
, Elena Pontarini
, Saba Nayar
, Joana Campos
, Francesca Arienzo
, Massimo Fusconi
, Bruna Cerbelli
, Carla Giordano
, Guido Valesini
, Michele Bombardieri
, Benjamin Fisher
, Francesca Barone

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

377 Downloads (Pure)

Abstract

OBJECTIVES: SS is an autoimmune condition characterized by systemic B-cell activation, autoantibody production and ectopic germinal centres' formation within the salivary gland (SG). The extent of SG infiltrate has been proposed as a biomarker of disease severity. Plasma levels of CXCL13 correlate with germinal centres' activity in animal models and disease severity in SS, suggesting its potential use as a surrogate serum marker to monitor local B-cell activation. The aim of this study was to evaluate the potential role of CXCL13 as a biomarker of SG pathology in two independent SS cohorts.

METHODS: 109 patients with SS were recruited at Sapienza University of Rome (Italy) (n = 60), or at Queen Elizabeth Hospital in Birmingham and Barts Health NHS Trust in London (n = 49). Both sera and matched minor SG biopsy were available. Sicca (n = 57) and healthy subjects' (n = 19) sera were used as control.

RESULTS: CXCL13 serum level was higher in SS patients compared with controls. Correlations between its serum levels and a series of histomorphological parameters, including size of the aggregates and the presence germinal centres', were observed.

CONCLUSION: Our data foster the use of CXCL13 to monitor the extent of local pathology in SS and its validation in longitudinal clinical studies.

Original language	English
Pages (from-to)	165-170
Number of pages	6
Journal	Rheumatology (Oxford, England)
Volume	59
Issue number	1
Early online date	4 Jul 2019
DOIs	https://doi.org/10.1093/rheumatology/kez255
Publication status	Published - 1 Jan 2020

Bibliographical note

Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

Keywords

Sjögren’s syndrome
biomarkers
histopathology
cytokines and inflammatory mediators
lymphocytes

Access to Document

10.1093/rheumatology/kez255Licence: None: All rights reserved

Serena_Colafrancesco_et_al_CXCL13_as_biomarker_for_histological_involvement_in_Sjögren’s_Syndrome_Rheumatology_2019
Checked for eligibility: 18/07/2019 This is a pre-copyedited, author-produced version of an article accepted for publication in Rheumatology following peer review. The version of record: Serena Colafrancesco et al, on behalf of ESSENTIAL (EULAR Sjögren's Syndrome Study Group) and HarmonicSS (H2020), CXCL13 as biomarker for histological involvement in Sjögren’s syndrome, Rheumatology, is available online at: https://doi.org/10.1093/rheumatology/kez255.
Accepted author manuscript, 171 KBLicence: None: All rights reserved

H2020_RIA_HARMONICSS
Barone, F. (Principal Investigator)
European Commission
1/01/17 → 31/12/20
Project: EU

Cite this

ESSENTIAL (EULAR Sjögren's Syndrome Study Group), HarmonicSS (H2020), Colafrancesco, S., Priori, R., Smith, C., Minniti, A., Iannizzotto, V., Pipi, E., Lucchesi, D., Pontarini, E., Nayar, S., Campos, J., Arienzo, F., Fusconi, M., Cerbelli, B., Giordano, C., Valesini, G., Bombardieri, M., Fisher, B., & Barone, F. (2020). CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome. Rheumatology (Oxford, England), 59(1), 165-170. https://doi.org/10.1093/rheumatology/kez255

@article{0d85055e046748d6bdb3aab5d475825b,

title = "CXCL13 as biomarker for histological involvement in Sj{\"o}gren{\textquoteright}s Syndrome",

abstract = "OBJECTIVES: SS is an autoimmune condition characterized by systemic B-cell activation, autoantibody production and ectopic germinal centres' formation within the salivary gland (SG). The extent of SG infiltrate has been proposed as a biomarker of disease severity. Plasma levels of CXCL13 correlate with germinal centres' activity in animal models and disease severity in SS, suggesting its potential use as a surrogate serum marker to monitor local B-cell activation. The aim of this study was to evaluate the potential role of CXCL13 as a biomarker of SG pathology in two independent SS cohorts. METHODS: 109 patients with SS were recruited at Sapienza University of Rome (Italy) (n = 60), or at Queen Elizabeth Hospital in Birmingham and Barts Health NHS Trust in London (n = 49). Both sera and matched minor SG biopsy were available. Sicca (n = 57) and healthy subjects' (n = 19) sera were used as control. RESULTS: CXCL13 serum level was higher in SS patients compared with controls. Correlations between its serum levels and a series of histomorphological parameters, including size of the aggregates and the presence germinal centres', were observed. CONCLUSION: Our data foster the use of CXCL13 to monitor the extent of local pathology in SS and its validation in longitudinal clinical studies.",

keywords = "Sj{\"o}gren{\textquoteright}s syndrome, biomarkers, histopathology, cytokines and inflammatory mediators, lymphocytes",

author = "\{ESSENTIAL (EULAR Sj{\"o}gren's Syndrome Study Group)\} and \{HarmonicSS (H2020)\} and Serena Colafrancesco and Roberta Priori and Charlotte Smith and Antonina Minniti and Valentina Iannizzotto and Elena Pipi and Davide Lucchesi and Elena Pontarini and Saba Nayar and Joana Campos and Francesca Arienzo and Massimo Fusconi and Bruna Cerbelli and Carla Giordano and Guido Valesini and Michele Bombardieri and Benjamin Fisher and Francesca Barone",

year = "2020",

month = jan,

day = "1",

doi = "10.1093/rheumatology/kez255",

language = "English",

volume = "59",

pages = "165--170",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "1",

}

ESSENTIAL (EULAR Sjögren's Syndrome Study Group), HarmonicSS (H2020), Colafrancesco, S, Priori, R, Smith, C, Minniti, A, Iannizzotto, V, Pipi, E, Lucchesi, D, Pontarini, E, Nayar, S, Campos, J, Arienzo, F, Fusconi, M, Cerbelli, B, Giordano, C, Valesini, G, Bombardieri, M, Fisher, B & Barone, F 2020, 'CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome', Rheumatology (Oxford, England), vol. 59, no. 1, pp. 165-170. https://doi.org/10.1093/rheumatology/kez255

TY - JOUR

T1 - CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome

AU - ESSENTIAL (EULAR Sjögren's Syndrome Study Group)

AU - HarmonicSS (H2020)

AU - Colafrancesco, Serena

AU - Priori, Roberta

AU - Smith, Charlotte

AU - Minniti, Antonina

AU - Iannizzotto, Valentina

AU - Pipi, Elena

AU - Lucchesi, Davide

AU - Pontarini, Elena

AU - Nayar, Saba

AU - Campos, Joana

AU - Arienzo, Francesca

AU - Fusconi, Massimo

AU - Cerbelli, Bruna

AU - Giordano, Carla

AU - Valesini, Guido

AU - Bombardieri, Michele

AU - Fisher, Benjamin

AU - Barone, Francesca

PY - 2020/1/1

Y1 - 2020/1/1

N2 - OBJECTIVES: SS is an autoimmune condition characterized by systemic B-cell activation, autoantibody production and ectopic germinal centres' formation within the salivary gland (SG). The extent of SG infiltrate has been proposed as a biomarker of disease severity. Plasma levels of CXCL13 correlate with germinal centres' activity in animal models and disease severity in SS, suggesting its potential use as a surrogate serum marker to monitor local B-cell activation. The aim of this study was to evaluate the potential role of CXCL13 as a biomarker of SG pathology in two independent SS cohorts. METHODS: 109 patients with SS were recruited at Sapienza University of Rome (Italy) (n = 60), or at Queen Elizabeth Hospital in Birmingham and Barts Health NHS Trust in London (n = 49). Both sera and matched minor SG biopsy were available. Sicca (n = 57) and healthy subjects' (n = 19) sera were used as control. RESULTS: CXCL13 serum level was higher in SS patients compared with controls. Correlations between its serum levels and a series of histomorphological parameters, including size of the aggregates and the presence germinal centres', were observed. CONCLUSION: Our data foster the use of CXCL13 to monitor the extent of local pathology in SS and its validation in longitudinal clinical studies.

AB - OBJECTIVES: SS is an autoimmune condition characterized by systemic B-cell activation, autoantibody production and ectopic germinal centres' formation within the salivary gland (SG). The extent of SG infiltrate has been proposed as a biomarker of disease severity. Plasma levels of CXCL13 correlate with germinal centres' activity in animal models and disease severity in SS, suggesting its potential use as a surrogate serum marker to monitor local B-cell activation. The aim of this study was to evaluate the potential role of CXCL13 as a biomarker of SG pathology in two independent SS cohorts. METHODS: 109 patients with SS were recruited at Sapienza University of Rome (Italy) (n = 60), or at Queen Elizabeth Hospital in Birmingham and Barts Health NHS Trust in London (n = 49). Both sera and matched minor SG biopsy were available. Sicca (n = 57) and healthy subjects' (n = 19) sera were used as control. RESULTS: CXCL13 serum level was higher in SS patients compared with controls. Correlations between its serum levels and a series of histomorphological parameters, including size of the aggregates and the presence germinal centres', were observed. CONCLUSION: Our data foster the use of CXCL13 to monitor the extent of local pathology in SS and its validation in longitudinal clinical studies.

KW - Sjögren’s syndrome

KW - biomarkers

KW - histopathology

KW - cytokines and inflammatory mediators

KW - lymphocytes

UR - https://www.scopus.com/pages/publications/85076449968

U2 - 10.1093/rheumatology/kez255

DO - 10.1093/rheumatology/kez255

M3 - Article

C2 - 31274159

SN - 1462-0324

VL - 59

SP - 165

EP - 170

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 1

ER -

CXCL13 as biomarker for histological involvement in Sjögren’s Syndrome

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Projects

H2020_RIA_HARMONICSS

Cite this